MARKET WATCH: Johnson & Johnson's stock drops to pace Dow decliners after appeals court ruling on Zytiga disappoints
Shares of Johnson & Johnson JNJ, +0.03% fell 3.3% in afternoon trade, enough to pace declines among its health care peers and among the Dow Jones Industrial Average's DJIA, +1.46% components, after reports that an appeals court ruled that J&J can't block sales of generic Zytiga while the company appeals the overturning of a Zytiga patent.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
XLV's Indicator enters downward trend
The Aroon Indicator for XLV entered a downward trend on September 22, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 161 similar instances where the Aroon Indicator formed such a pattern. In 137 of the 161 cases the stock moved lower. This puts the odds of a downward move at 85%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XLV as a result. In 70 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for XLV turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 40 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
XLV moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +0.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where XLV advanced for three days, in 267 of 327 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
XLV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Category Health
Advertisement